

7/26/2018; Page 1

Suggested Formula	Acetaminophen 100 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 007 858	
----------------------	--	-----	-----------	--

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Acetaminophen, USP	10.000	g				
Stevia Powder	0.50	g				
Methylcellulose Gel (1%)	10.0	mL				
Methylcellulose Gel (1%)	q.s. to 100.0	mL				

WHERE WORK



/	technicalservices@me	<u>disca.net</u>		7/26/2018; Page 2	
Suggested Formula Acetaminophen 100 n	ng/mL Oral Liquid (Suspension, 1	00 mL)	FIN	F 007 858	
PECIAL PREPARATORY CONS	IDERATIONS				
Ingredient-Specific Information					
Light Sensitive (protect from l	ight whenever possible):	Acetaminophen			
Hygroscopic (protect from mo	isture whenever possible):	Stevia Powder, Glycerin			
Moisture Sensitive (protect fro	om humidity whenever possible):	Acetaminophen			
Suggested Preparatory Guidelines					
Non-Sterile Prepara	tion Sterile Preparation	Cr+			
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error measure an additional 5 to 9% o				
Special Instruction:	 This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings was formally published February 1, 2016 in the First Supplement to USP 39-NF 34 and has a delayed official implementation date of December 31st, 2019. This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within USP 795 and USP 800, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula. 				
	All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.				
	If applicable, follow all required not limited to procurement, trans clean up (spills) & disposal.				
	If you are a registered 503B facility including but not limited to the C Industry (GFIs) and Compliance	Code of Federal Regulations (O			
	This procedure requires the use of and preparation techniques must				



7/26/2018; Page 3

Suggested Formula	Acetaminophen 100 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 007 858	
----------------------	--	-----	-----------	--

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Acetaminophen, USP	10.000	g			
Stevia Powder	0.50	g			
Methylcellulose Gel (1%)	10.0	mL	(Q)		
Methylcellulose Gel (1%)	q.s. to 100.0	mL	2		

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

	Preparatory Instruction					
1.	Powder-liquid preparation: A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend: -Acetaminophen -Stevia Powder B. Levigate the fine, homogeneous powder blend (Step 1A) with the Methylcellulose Gel (1%) (10.0 mL <i>plus</i> processing error adjustments). End result: Homogeneous paste-like dispersion.					
2.	Filling to volume: A. Add additional Methylcellulose Gel (1%) to the Homogeneous paste-like dispersion (Step 1B) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments). Specifications: Continuously mix until homogenous. End result: Homogeneous liquid-like dispersion.					
3.	Product transfer: A. Transfer the final product into the specified dispensing container (see "Packaging Requirements"). Note: Continuously mix the final product during the transfer process in order to maintain homogeneity.					



7/26/2018; Page 4

Sugger Form	Acetaminophen 100 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 007 858	
----------------	--	-----	-----------	--

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated, as per USP.	Packaging Requirements		 Tightly closed, light resistant dispensing bottle. To be administered with a metered dose- measuring device.
	1	Use as directed. Do not exceed dose.	prescribed	6	Keep out of reach of children.
Auxiliary Labels	2	Protect from light.		7	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
Labels	3	Shake well before use.		8	Cap tightly after use.
	4	Do not take with alcohol, tranquilizers or other CNS depres		9	Keep in a dry place.
	5	Keep refrigerated. Do not freeze.			
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary				nsing container as deemed necessary.	
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	actior	15.



7/26/2018; Page 5

		Suggested Formula Acetaminophen 100 mg/mL Oral Liquid (Suspension, 100 mL)		FIN	F 007 858				
RE	FERENCES								
	1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.</i> American Pharmacists Association; 2016: 279.							
	2.	Methylcellulose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 th Edition. American Pharmaceutical Association; 2012: 496.							
	3.	Paracetamol. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 108.							
	4.	Acetaminophen (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #47.							
	5.	Acetaminophen. In: Trissel LA. Trissel's Stability of Compounded Formulations, 5th Edition. American Pharmaceutical Association; 2012: 2.							
	6.	Acetaminophen (Monograph). United States Pharmacopeia XLI / National Formulary 36. Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 34.							
	7.		795>. United States Pharmacopeia XL / National Formulary 35. Rockville, MD. US Ph 16: 675.	armaco	opeial Convention,				

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.